Valuation: Pulmatrix, Inc.

Market Cap 6.1M 5.32M 4.96M 4.56M 8.56M 583M 8.77M 58.82M 22.98M 289M 22.9M 22.4M 996M P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 2.01M 1.75M 1.64M 1.5M 2.82M 192M 2.89M 19.4M 7.58M 95.3M 7.55M 7.39M 329M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 -
1 day-0.60%
1 week-1.76%
Current month-1.76%
1 month+1.83%
3 months+30.47%
6 months-37.46%
Current year-25.11%
1 week 1.64
Extreme 1.635
1.8
1 month 1.56
Extreme 1.557
1.88
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
5.76
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
20.8
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 19/07/2024
Director TitleAgeSince
Director/Board Member 58 31/10/2019
Director/Board Member 57 22/06/2020
Director/Board Member 55 30/09/2020
Date Insider Type Main position Quantity % Market Cap.
26/01/23 Free

Chief Executive Officer

34,900 0.9590%
26/01/23 Free

Director

1,700 0.0467%
26/01/23 Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%-1.76%-68.27%-36.98% 6.14M
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.52%-0.62%+26.84%+145.35% 23.72B
Weighted average by Cap. +0.28%-0.20%+35.95%+130.61%

Financials

2024 2025
Net sales 7.81M 6.81M 6.35M 5.84M 10.96M 747M 11.22M 75.27M 29.41M 370M 29.31M 28.67M 1.28B -
Net income -9.56M -8.34M -7.78M -7.15M -13.42M -914M -13.74M -92.18M -36.02M -453M -35.89M -35.11M -1.56B -5.16M -4.5M -4.2M -3.86M -7.25M -494M -7.42M -49.78M -19.45M -245M -19.38M -18.96M -843M
Net Debt -9.52M -8.3M -7.75M -7.12M -13.37M -911M -13.68M -91.81M -35.88M -451M -35.74M -34.97M -1.56B -4.09M -3.57M -3.33M -3.06M -5.74M -391M -5.88M -39.42M -15.4M -194M -15.35M -15.01M -668M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
29/07/26 US$1.670 -0.60% 17,683
28/07/26 US$1.680 -2.89% 11,835
27/07/26 US$1.730 +4.85% 9,127
24/07/26 US$1.650 -6.78% 14,873
23/07/26 US$1.770 +4.73% 20,570
  1. Stock Market
  2. Stocks
  3. PULM Stock